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The purpose of this study was to describe the clinical implementation of a magnetic 
resonance image (MRI)-based approach for adaptive intracavitary brachytherapy 
(ICBT) of cervix cancer patients. Patients were implanted with titanium tandem and 
colpostats. MR imaging was performed on a 1.5-T Philips scanner using T2-weighted 
(T2W), proton-density weighted (PDW), and diffusion-weighted (DW) imaging 
sequences. Apparent diffusion coefficient (ADC) maps were generated from the 
DW images. All images were fused. T2W images were used for the definition of 
organs at risk (OARs) and dose points. ADC maps in conjunction with T2W images 
were used for target delineation. PDW images were used for applicator definition. 
Forward treatment planning was performed using standard source distribution rules 
normalized to Point A. Point doses and dose-volume parameters for the tumor and 
OARs were exported to an automated dose-tracking application. Brachytherapy doses 
were adapted for tumor shrinkage and OAR variations during the course of therapy. 
The MRI-based ICBT approach described here has been clinically implemented 
and is carried out for each brachytherapy fraction. Total procedure time from patient 
preparation to delivery of treatment is typically 2 hrs. Implementation of our tech-
nique for structure delineation, applicator definition, dose tracking, and adaptation is 
demonstrated using treated patient examples. Based on published recommendations 
and our clinical experience in the radiation treatment of cervix cancer patients, we 
have refined our standard approach to ICBT by 1) incorporating a multisequence 
MRI technique for improved visualization of the target, OARs, and applicator, and by  
2) implementing dose adaptation by use of automated dose tracking tools. 
PACS numbers: 87.61.-c, 87.53.Jw, 87.19.xj




Three-dimensional (3D)-based intracavitary brachytherapy (ICBT) treatment planning for 
cervical cancer was implemented by the Groupe Européen de Curiethérapie-European Society 
for Radiotherapy & Oncology (GEC-ESTRO) working group, providing guidelines on the use 
of magnetic resonance imaging (MRI), primarily T2-weighted (T2W) sequences, for target 
definition.(1,2) These guidelines have been implemented at some institutions with access to 
MRI units and, over time, have facilitated a transition from Point A-based dose prescriptions to 
dose-volume adaptation.(3-7) An increase in local control and improvement in overall survival 
using MRI-assisted, dose-volume adaptation for ICBT, combined with 3D conformal EBRT, 
has been reported by one of these institutions.(8,9) 
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At our institution, our standard approach for cervix cancer treatment — 25–28 fractions of 
positron emission tomography/computed tomography intensity-modulated radiation therapy 
(PET/CT-guided IMRT) combined with six weekly fractions of either film-based or CT-based 
high dose rate (HDR) ICBT using standard source distribution rules normalized to Point A — was 
performed from 1997–2008 and the results of this approach have been published previously.(10) 
Since then, we have found that T2W-MRI fused with other MRI sequences can assist with target 
volume delineation (via diffusion-weighted imaging, DWI) and with applicator reconstruction 
(via proton density-weighted imaging, PDW).(11-13) We have used this multisequence MRI tech-
nique for ICBT treatment planning in addition to FDG-PET/CT imaging for IMRT treatment 
planning, and have reported our analysis of dose-volume parameters predicting gross tumor 
volume (GTV) control using this treatment technique.(14) Total dose delivered to the GTV from 
combined MRI-based HDR and PET/CT-guided IMRT was found to be highly correlated with 
local tumor control.(14) With this information in hand, we have further refined our brachytherapy 
treatment technique to include dose tracking and adaptation, similar to what has been done by 
institutions that have implemented GEC-ESTRO recommendations.(8,15) 
Here we describe the implementation of the multisequence MRI technique using T2W, DW, 
and PDW sequences for ICBT planning of cervix cancer patients. We also describe how we 
perform brachytherapy dose adaptation by tracking tumor volumes, tumor doses, and organs at 
risk (OAR) doses over the course of treatment, using an automated dose-tracking application.
(16) We have clinically implemented these methods at our facility and, using treated patients as 
examples, we demonstrate features of our MRI-based technique for adaptive ICBT. 
 
II. MATERIALS AND METHODS
A.  Treatment prescription guidelines
All cervix cancer patients underwent FDG-PET/CT simulation and were treated with IMRT, as 
described previously.(10) Contoured nodal areas included the pelvic, inguinal, and if involved, 
para-aortic lymph nodes with a 0.7 cm expansion excluding bony anatomy to form a nodal 
clinical target volume (CTVnodal). Metabolically active lymph nodes were contoured as a nodal 
metabolic target volume (MTVnodal). The nodal planning target volume (PTVnodal) included 
the CTVnodal expanded by 0.5 cm, and then added to the MTVnodal. The MTVcervix was 
defined as the 40% threshold volume.(17) Patients were prescribed to receive IMRT treatment 
to the MTVcervix, MTVnodal, and PTVnodal to the dose levels specified in Table 1 in 1.8 Gy 
Table 1. Treatment guidelines for carcinoma of the intact cervix.
  IMRTa 
     Para-Aortic
    PTV and/or HDR Brachytherapy
   MTV Pelvic Pelvic MTV Dose to Point A
   Cervix Nodes Nodal (cGy) in
  Tumor Stage  (cGy) (cGy) (cGy) 6 Fractions
 Carcinoma
 in situ  in situ Ia1 0 0 0 3420
 Ia2,  Ib (< 10 cc) 0 4500 0 3420
 Ib1, IIa (10–30 cc) 1000 5040 5040 3420
 Ib2, IIa, IIb (30–60 cc) 2000 5040 5040 3900
 IIb, III (60–120 cc) 2000 5040 5040 4140
 III (> 120 cc) 2000 5040 5040 4380
 IIB, Suboptimal 
 IIIB, Brachytherapy due to 
 IV tumor anatomy 
7020 4992 4992 0
a PTV fractionation is 180 cGy per fraction with MTV Cervix treated simultaneously. 
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fractions four days per week with HDR brachytherapy delivered one day of the week, in six 
weekly fractions. Below, we describe in more detail the techniques implemented for each 
brachytherapy fraction. 
B.  Imaging
All patients reviewed an MRI safety questionnaire prior to each implant. Patients were implanted 
with a titanium tandem and colpostat applicator (Varian Medical Systems, Inc., Palo Alto, CA) 
in a semisterile environment. Either saline-soaked gauze or saline-filled balloon packing (Alatus 
Vaginal Balloon Packing System, Radiadyne LLC., Houston, TX), was used to immobilize 
the implanted applicator within the patient, as well as provide distance between the applicator 
and adjacent OARs. Prior to imaging, 1 mg glucagon subcutaneous was also given to some 
patients to reduce bowel motion. Imaging was performed on a 1.5-T MR scanner (Intera, 
Philips Medical Systems, Inc., Cleveland, OH). Patients were positioned supine with body/
pelvis phased array surface coils. MR scanning sequences included T2W turbo spin echo (TSE) 
(TR = (3200-6500) ms, TE = 100 ms, in-plane resolution 0.1 cm, section thickness 0.5 cm, 
sagittal and axial acquisition planes), single-shot DW echoplanar (TR = 1300 ms, TE = 75 ms, 
in-plane resolution 0.2 cm, section thickness 0.5 cm, sagittal acquisition planes) at b values of 
0 and 800 s/mm2, with diffusion gradients applied in all three directions, and PDW TSE (TR = 
(3000-6000) ms, TE = 5.5 ms, in-plane resolution 0.1 cm, section thickness 0.25 cm, sagittal 
acquisition planes), zero gap, foldover in the foot–head direction, 3–6 min per sequence. Imaging 
extents were set approximately from L4 to the ischial tuberosities in the craniocaudal direc-
tion, from the abdominal wall to the sacrum in the anterior–posterior direction, and were set to 
include the iliac crests in the transverse direction. Apparent diffusion coefficient (ADC) maps 
were generated from the DW-MRI on the scanner console software in the following manner:
  (1)
 
where SDW and So are signal intensities measured with and without diffusion-weighted gradients, 
respectively, and the b value represents the diffusion factor.(18) It has been shown previously that 
ADC values in tumors are generally less than those in benign tissues, appearing hypointense 
in the images.(18-21)
C.  Treatment planning 
T2W images, PDW images, and ADC maps were transferred to a radiation therapy treatment 
planning system (BrachyVision TPS, Varian Medical Systems, Inc., Palo Alto, CA) for contour-
ing and isodose planning. Because the images were acquired in the same imaging session, the 
datasets upon import into the TPS were automatically registered based on their shared frame of 
reference and then manually verified using the applicator and surrounding anatomy. T2W images 
were utilized for contouring of OARs (i.e., bladder, rectum, and sigmoid). Point A was defined 
relative to the applicator using the classical definition on the T2W images.(7) The delineation 
of the GTV, defined as the primary cervical gross tumor volume, was generally carried out on 
the T2W images, then verified against the registered ADC map and, if necessary, adjusted to 
improve agreement. The PDW images were used for reconstruction of the intrauterine tandem 
and the vaginal colpostats using the signal void resulting from the titanium applicator.(22) 
Forward treatment planning was performed using standard source distribution rules with a dose 
of 6.5 Gy/fraction normalized to Point A.
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D.  Dose tracking and adaptation  
The Digital Imaging and Communications in Medicine (DICOM) standard radiation therapy 
(RT) dose, plan, and structure files were exported from the TPS to an automated dose tracking 
application referred to as the “HDR Dose Tool” (MATLAB, MathWorks, Inc., Natick, MA). 
The HDR Dose Tool was used to create an HTML-based spreadsheet which tracked external 
beam dose and brachytherapy dose, as well as cumulative doses.(16) Some examples of dose 
tracking parameters recorded on the spreadsheet included the mean Point A dose, target vol-
ume dose metrics (e.g., mean dose, volume of GTV receiving prescription dose (V100), and 
doses to 100% and 90% of GTV (D100 and D90)), and the minimum doses to the maximally 
exposed 2 cm3 of the OARs (D2cc). The doses were also normalized to their equivalent dose 
in 2 Gy fractions (EQD2).
(15) 
Dose adaptation may have been performed if the fractional D2cc to the OARs was greater than 
some threshold (i.e., 70%–80% of mean Point A dose) and if the cumulative D2cc was greater 
than some threshold (90 Gyαβ3 for bladder, 75 Gyαβ3 for rectum and sigmoid, as recommended 
by other adopters of MR-based ICBT).(8,15) Dose adaptation, if necessary, was carried out via 
two different approaches. The first, more traditional, approach involved making modifications 
in applicator geometry (e.g., mini-ovoids used in place of standard-sized ovoids to reduce 
OAR doses). This form of dose adaptation, referred to as “applicator optimization”, could be 
performed with or without “weighting optimization” where all dwell weights resulting from the 
standard source distribution rules were scaled down uniformly.(8) Weighting optimization was 
usually performed after fraction 3, given adequate tumor volume shrinkage (> 50% reduction), 
and usually involved decreases in dwell weights of either 10% or 20%, while maintaining the 
V100 for that fraction ≥ 90%. Thus, weighting optimization yielded symmetric decreases of 
the dwell times with the dwell positions left intact. Even if the doses to OARs were greater 
than the respective thresholds in the first half of treatment, tumor dosage took priority, and the 
standard source distribution rules were followed for the first half of treatment.
 
III. RESULTS 
Below we demonstrate the use of our techniques on three of our patients who were enrolled on 
a research protocol approved by the Human Research Protection Office. 
A.  Examples for the delineation of OARs and GTV
Figure 1 demonstrates the use of the registered T2W images and ADC maps for target delinea-
tion for Patient 1, diagnosed with Stage IIB cervix cancer. Note in Fig. 1 the good agreement 
in target delineation between corresponding slices on the T2W image and ADC map. Figure 2 
shows a different slice containing the tandem for the same image datasets, and demonstrates a 
potential pitfall of the ADC maps which is the presence of distortions due to the metal appli-
cator. The borders of the target appear distorted and delineation on the ADC map was done 
with caution, especially for target slices near the titanium tandem. These distortions are local 
to regions immediately surrounding the tandem applicator, as demonstrated by the undistorted 
boundaries of the vertebral bodies and bladder in the ADC map. Note, due to the otherwise poor 
image quality of the ADC maps, the ADC maps cannot be used for the delineation of OARs, 
which is limited to the T2W images.
Figure 3 shows the advantage of ADC maps for visualization of tumor borders for Patient 2, 
diagnosed with Stage IIB cervix cancer. In this case, the tumor borders on the T2W-MRI were 
not very distinct, but become more obvious after verification against the ADC map. 
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Fig. 1. A parasagittal slice in the T2W image dataset (a) and the corresponding slice in the ADC map (b) about 1.5 cm 
lateral to the tandem for Patient 1. The same slices in the T2W image dataset (c) and ADC map (d) displayed with the 
contour for GTV (in red). Organ-at-risk contours for bladder (yellow) and sigmoid (light green) are displayed on the 
T2W images (a) and (c).
Fig. 2. Another parasagittal slice in the T2W image dataset (a) and the corresponding slice in the ADC map (b) containing 
the tandem for Patient 1. The same slices in the T2W image dataset (c) and the ADC map (d) displayed with the contours 
for the GTV (in red). Organ-at-risk contours for bladder (yellow) and sigmoid (light green) are displayed on the T2W 
images (a) and (c).
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B.  Examples of applicator reconstruction
Figure 4 displays parasagittal and paracoronal views of an implant for Patient 3 diagnosed 
with Stage IIIB cervix cancer. These views demonstrate how use of the PDW, registered to the 
T2W-MRI, yields improved visualization of the tandem (dark) from the background (bright). 
In the reconstructed paracoronal views (Figs. 4(c) and 4(d)), the tandem is especially difficult 
to discern from the background in the T2W dataset due to the greater slice thickness (0.5 cm) 
needed to maintain acceptable signal in the T2W dataset. The higher signal achieved with PDW 
sequences allows the use of thinner slices (0.25 cm) and improved visualization in the recon-
structed views. Note, however, due to the more limited soft tissue contrast, the PDW should 
be limited to applicator definition only. 
Fig. 3. A parasagittal slice in the T2W image dataset (a) and the corresponding slice in the ADC map (b) for Patient 2. The 
same slices in the T2W image dataset (c) and ADC map (d) displayed with the contour for GTV (in red). Organ-at-risk 
contours for bladder (yellow), rectum (brown), and sigmoid (light green) are displayed on the T2W images (a) and (c).
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C.  Examples of dose adaptation 
Figure 5 displays an example of weighting optimization for Patient 1. For the first 4 fractions, 
the D2cc bladder was steadily increasing (i.e., from 100% to 119% of mean Point A dose) as 
the tumor responded to treatment, shifting the bladder closer to the applicator. The D2cc rectum 
varied between 80%–90% of mean Point A dose. By fraction 5, the GTV had decreased from 
an initial volume of 39.6 to 8.7 cc. The tumor shrinkage was considered to be adequate, and the 
bladder and rectal doses considered high enough to warrant de-escalation of the dwell weights 
by 20% for fraction 5. The same magnitude of de-escalation was applied for fraction 6 with the 
V100 at about 89%. These decreases in dwell weighting did help keep the cumulative D2cc for 
rectum and bladder at approximately 70 Gyαβ3 and 116 Gyαβ3, respectively. However, no further 
attempts were made to decrease the bladder D2cc in an effort to preserve target dose coverage. 
Figure 6 displays an example of applicator optimization for Patient 3. Because of anatomical 
changes that are typically observed as treatment progresses (e.g., tumor shrinkage and nar-
rowing of vaginal fornices), the ovoid separation for Patient 3 decreased from 4.0 to 3.2 cm 
during the first 3 fractions, and consequently, the D2cc rectum increased from 80% to 106% 
of mean Point A dose. By fractions 4 and 5, the patient’s anatomy pushed the ovoids to be too 
anterior, and as a result, the ovoids were not contributing significantly to GTV coverage, and 
were giving unnecessary dose to the OARs. Thus, the ovoids were not activated for fraction 
4–5, decreasing rectal dose to about 40% of mean Point A dose. By fraction 6, the tandem was 
implanted only and was sufficient for GTV coverage. The modifications in applicator geometry 
did help keep the cumulative D2cc for rectum and bladder to be approximately 67 Gyαβ3  and 
105 Gyαβ3, respectively, with the V100 at 100% for every fraction. Although not attempted for 
this patient, weighting optimization may have also been used for the last few fractions of this 
patient to attempt to reduce bladder D2cc even further because of the generous target coverage.
 
Fig. 4. A parasagittal slice displaying the tandem (as indicated by the arrow) relative to the surrounding anatomy in the 
T2W-MRI (a) and in the corresponding slice in the PDW-MRI (b) for Patient 3. For the same dataset, a paracoronal slice 
displaying the tandem (as indicated by the arrow) in the T2W-MRI (c) and in the corresponding slice in the PDW-MRI (d). 
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Fig. 5. Parasagittal slices from T2W datasets for fractions 1–6 ((a)-(f)) for Patient 1, displaying the prescription isodoses 
(in green) relative to the shrinking tumor volume (in red) and OARs (bladder in yellow, rectum in brown, and sigmoid 
in light green). Ovoids (not shown) were implanted and activated for all fractions.  Weighting optimization was used for 
fractions 5–6.  
Fig. 6. Parasagittal slices from T2W datasets for fractions 1–6 ((a)-(f)) for Patient 3, displaying the prescription isodose 
(in green) relative to the shrinking tumor volume (in red) and OARs (bladder in yellow, rectum in brown, and sigmoid in 
light green). Ovoids were implanted for first 5 fractions, but not activated for fractions 4–5. No ovoids were implanted 
for the last fraction.  
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IV. DISCUSSION
Our standard approach for cervix cancer treatment, PET/CT-guided IMRT combined with either 
film-based or CT-based HDR ICBT, using standard source distribution rules normalized to Point 
A, has been performed for years.(10) We have refined the approach for ICBT by incorporating 
advanced MRI techniques and automated dose tracking tools to perform dose adaptation dur-
ing the brachytherapy treatment. Below, we discuss certain aspects of our approach within the 
context of GEC-ESTRO recommendations and the experience of institutions that have adopted 
their recommendations.
With regard to MR imaging, GEC-ESTRO describes the use of T2W-MRI as the gold standard 
for tumor and critical structure visualization and as having sufficient contrast for applicator 
definition based on their experience with 0.2-T and 1.5-T MRI units, with the use of additional 
MRI sequences to be considered optional.(23) While we also advocate the use of T2W-MRI for 
ICBT, we recommend the use of additional MRI sequences for improved visualization of the 
target and critical structures using a combination of T2W imaging and DW-ADC mapping and, 
in addition, for improved visualization of the applicator using PDW images.(11,12) Although 
we make no formal recommendations regarding the choice of MRI scanner for ICBT treat-
ment planning, our brachytherapy technique is based on a 1.5-T MRI scanner and may not 
readily apply to higher magnetic field strengths (i.e., 3-T) due to the increased image distor-
tion and susceptibility artifacts, in particular, those associated with a titanium applicator.(24) A 
number of authors have described how titanium applicators, while MRI-compatible, can also 
introduce susceptibility artifacts in the images, and that these artifacts are dependent on image 
sequence.(22,24) Therefore, similar to GEC-ESTRO, we recommend that, in addition to CT scans, 
phantom MRI scans be acquired with clinical sequences as part of applicator commissioning. 
These scans should then be fused to one another to understand the nature of these artifacts and 
their effect on applicator geometry in the MR images.(25) 
With regard to dose adaptation, Kirisits et al.(8) describe a form of dose adaptation where one 
starts with standard source distribution rules normalized to Point A, and then performs sym-
metric, asymmetric, or more customized modifications of the dwell weights and positions with 
a ring and tandem applicator. Our dose adaptation approach is similar, but is currently limited 
to symmetric decreases of the dwell weights only to reduce the doses to OARs. Similar to our 
approach, Kirisits and colleagues used optimization to reduce OAR dose. However, a key dif-
ference from our approach is that the Kirisits study also optimized target dose coverage. The 
rationale behind our current dose adaptation scheme is to use the standard source loading patterns 
to treat the tumor, and if the GTV is reduced in volume by about 50%, to dose  de-escalate for the 
remaining 2 to 3 fractions to reduce OAR dose while maintaining at least 90% coverage of the 
GTV by prescription. Currently, the triggers for optimization in our technique are largely based 
on shrinkage of the GTV and also on OAR dose. Future development of our dose adaptation 
approach will include target dose optimization, and perhaps dose escalation, for those tumor 
volumes that do not respond over the course of treatment. This may involve varying individual 
dwell weights and dwell positions, similar to what was done by Kirisits et al.(8) Potter et al.,(9) 
who did implement the methods of the Kirisits study to perform MRI-assisted dose-volume 
adaptation, as well as dose escalation, reported in their single center an increase in local control 
and improvement in overall survival. Thus, there may be some benefit to incorporating target 
dose adaptation and dose escalation into our approach, as well.
GEC-ESTRO recommendations for ICBT planning consider the dose-volume coverage of 
a GTV as well as of a high-risk clinical target volume (HR-CTV), whereas our technique only 
tracks the GTV, defined as gross tumor and not including any expansions or “gray” zones.(1) 
We chose to define GTV alone as the target volume as a simple, reproducible method for target 
definition using the DW–ADC maps in conjunction with T2W-MRI. The utility of DW–ADC 
maps for identifying cancerous regions in the cervix has been demonstrated in the literature.(18-21) 
Preliminary work has shown good agreement (Dice Similarity Coefficient = 0.76 ± 0.06) 
130  Zoberi et al.: MRI-based adaptive intracavitary brachytherapy 130
Journal of Applied Clinical Medical Physics, Vol. 17, No. 1, 2016
between tumor volumes delineated on DW–ADC maps and on FDG-PET images of cervix 
cancer patients.(13) Dyk et al.(14) showed that dose to the GTV from our treatment approach of 
combined MRI-based HDR and PET/CT-guided IMRT is highly correlated with local tumor 
control. GTV doses correlated with ≥ 90% local control included the D100 (> 69 Gy), D90 
(> 98 Gy), and Dmean (> 260 Gy). Thus, to ensure these levels of local control with our dose 
adaptation approach, we will continue to define the GTV, as described here, as the sole target 
of interest, and will also consider these GTV dose metrics when performing dose adaptation. 
 
V. CONCLUSIONS
Using our refined approach for MR-based ICBT, we can perform multisequence imaging, 
automated dose tracking, and dose adaptation, and keep the time between implant and treat-
ment delivery to within 2 hours. Although it may not be feasible for some clinics to implement 
all of the techniques as described here due to limited resources or established practices, we 
do believe that implementation of certain aspects of our technique will be of value to clinics 
performing MR-based ICBT. Implementation of the multisequence MRI technique as described 
here will be of value for improved visualization of the target volume, critical structures, and 
applicator. Also, implementation of the dose tracking tools and dose adaptation technique by 
simply de-escalating Point A-based brachytherapy dose distributions will help balance target 
volume coverage with OAR sparing, without the need for more complex adaptation schemes. 
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